Oruka Therapeutics Announced A Private Investment In Public Equity Financing For Gross Proceeds Of Approximately $200M, Offering 5.6M Shares At $23/Share, 2,439 Shares Of Its Series A Non-voting Convertible Preferred Stock At $23,000 Per Share, And...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.